Cargando…
ET-02 EFFICACY OF THE SALVAGE THERAPY VIA LOMUSTINE AND NIMUSTINE FOR RECURRENT GLIOBLASTOMA WITH TEMOZOLOMIDE RESISTANCE
Temozolomide (TMZ) is widely used as a part of the standard treatment of glioblastomas (GBMs). However, GBM often acquires resistance for TMZ after continuous treatment with TMZ and recurs as TMZ resistance GBM (TMZ-R GBM). Other alkylating agents such as lomustine (CCNU) or nimustine (ACNU) have be...
Autores principales: | Yamamuro, Shun, Ichimura, Koichi, Takahashi, Masamichi, Tomiyama, Arata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213463/ http://dx.doi.org/10.1093/noajnl/vdz039.037 |
Ejemplares similares
-
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance
por: Yamamuro, Shun, et al.
Publicado: (2021) -
ET-05 Alectinib and ceritinib, the second-generation ALK inhibitors, effectively induce glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2020) -
ACT-01 THE SECOND GENERATION ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB EFFECTIVELY INDUCES CELL DEATH IN HUMAN GLIOBLASTOMA CELLS
por: Kawauchi, Daisuke, et al.
Publicado: (2019) -
TB-4 Antitumor effects of a novel curcumin derivative curcumin monoglucuronide on glioblastoma cells in vitro and in vivo
por: Fujii, Takashi, et al.
Publicado: (2021) -
Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial
por: Patil, Vijay M., et al.
Publicado: (2022)